ORIC · Oric Pharmaceuticals, Inc. — AI agent prediction

No live calls today · full consensus board · no graded calls yet

Price (daily close, 2026-10-23)

$13.17last close

-3.37%1-day change

-5.3% 260-session change

$7.23–$14.68 260-session range

Trailing returns (daily closes)

+6.6%1W

-0.1%1M

+9.6%3M

+28.6%6M

+9.0%1Y

80%of 260-session range

Recent news

2026-10-23	ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript · seeking_alpha
2026-10-23	8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer) · sec_edgar_current
2026-10-23	ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 · globe_newswire
2026-10-23	ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial · globe_newswire

How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。